Literature DB >> 11873255

The effects of immunization with recombinant Sm14 (rSm14) in reducing worm burden and mortality of mice infected with Schistosoma mansoni.

Fábio Ribeiro1, Cristiane dos Santos Vieira, Adriana Fernandes, Neusa Araujo, Naftale Katz.   

Abstract

To investigate whether mice immunization with the recombinant form of a 14.7 KDa Schistosoma mansoni protein (rSm14) confers protection against a S. mansoni lethal challenge infection, rSm14-immunized mice were challenged with different cercarial burdens. A significant protection was detected in immunized mice challenged with 100 or 1,000 S. mansoni cercariae when compared with their controls (p< 0.004 and p< 0.01 respectively). Differently from previous report, none of the mice from the control group (not immunized and infected with 1000 cercariae) died before the 30th day post-infection. A direct correlation between the number of challenge cercariae and the precocity of mice death was found. IgM anti-rSm14 antibodies were significantly produced (p< 0.05) mainly in the groups of immunized mice infected with 500 or 1000 cercariae. IgG and IgA anti-rSm14 antibodies were not significantly detected. In Western immunoblots, all mice sera showed a specific antibody response with a 14.7 KDa antigen being reacted with particular intensity in sera from immunized mice. The results show that immunization with rSm14 reduced mice worm burden independently of the cercariae load of challenge infection. No correlation was found between serum antibodies and worm burden reduction. In relation to cercarial load and the rate and precocity of mice mortality a direct correlation was found.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873255     DOI: 10.1590/s0037-86822002000100003

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.

Authors:  Shereen F Mossallam; Eglal I Amer; Radwa E Ewaisha; Amal M Khalil; Hamida M Aboushleib; Mohammed Bahey-El-Din
Journal:  BMC Infect Dis       Date:  2015-03-24       Impact factor: 3.090

Review 2.  Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

Authors:  Emmanuella Driciru; Jan Pieter R Koopman; Stephen Cose; Afzal A Siddiqui; Maria Yazdanbakhsh; Alison M Elliott; Meta Roestenberg
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.